Satoh, Taroh
Kang, Yoon-Koo
Chao, Yee
Ryu, Min-Hee
Kato, Ken
Cheol Chung, Hyun
Chen, Jen-Shi
Muro, Kei
Ki Kang, Won
Yeh, Kun-Huei
Yoshikawa, Takaki
Oh, Sang Cheul
Bai, Li-Yuan
Tamura, Takao
Lee, Keun-Wook
Hamamoto, Yasuo
Kim, Jong Gwang
Chin, Keisho
Oh, Do-Youn
Minashi, Keiko
Cho, Jae Yong
Tsuda, Masahiro
Tanimoto, Mitsunobu
Chen, Li-Tzong
Boku, Narikazu
Funding for this research was provided by:
Funded by Ono Pharmaceutical Co., Ltd., Osaka, Japan, and Bristol-Myers Squibb, Inc., Princeton, NJ. (NA)
Article History
Received: 11 February 2019
Accepted: 29 April 2019
First Online: 13 May 2019
Compliance with ethical standards
:
: Taroh Satoh received donations for his department from Ono Pharmaceutical, Yakult Honsha, and Chugai Pharmaceutical and received research grants and honoraria from Ono Pharmaceutical, Yakult Honsha, Chugai Pharmaceutical, Eli Lilly, Bristol Myers Squibb, Merck Serono, Takeda Pharmaceutical, Taiho Pharmaceutical, and MSD. Yoon-Koo Kang is a consultant for Ono Pharmaceutical, Bristol Myers Squibb, Daehwa Pharmaceutical, LSK Biopharma, AstraZeneca, Merck Serono, and Novartis. Min-Hee Ryu received honorarium and served on the advisory boards for Ono Pharmaceutical, Bristol Myers Squibb, MSD, Eli Lilly, Taiho Pharmaceutical, Novartis, and Daehwa Pharmaceutical. Ken Kato received research grants from Ono Pharmaceutical, MSD, Shionogi, Merck Serono, and Beigene. Hyun Cheol Chung received research grants from Ono Pharmaceutical, Eli Lilly, GSK, MSD, Merck Serono, and Taiho Pharmaceutical, honoraria from Merck Serono, Eli Lilly, and Foundation Medicine/Roche, and consultation fees from Taiho Pharmaceutical, Celltrion, MSD, Eli Lilly, Quintiles, BMS, and Merck Serono. Jen-Shi Chen received research grants and consulting fees from Ono Pharmaceutical. Kei Muro received research grants from Ono Pharmaceutical, MSD, Daiichi Sankyo, Kyowa Hakko Kirin, Shionogi Pharmaceutical, and Gilead Sciences and personal fees from Chugai Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Merck Serono, Eli Lilly, and Yakult Honsha. Kun-Huei Yeh received personal fees from Ono Pharmaceutical, Boehringer Ingelheim, Takeda Pharmaceutical, Bristol Myers Squibb, MSD, Eli Lilly, and Amgen. Takaki Yoshikawa received research grants from Ono Pharmaceutical and Bristol Myers Squibb, Chugai Pharmaceutical, and Taiho Pharmaceutical, honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, Bristol Myers Squibb, Ono Pharmaceutical, Eli Lilly, Yakult Honsha, Nippon Kayaku, Johnson and Johnson, Covidien, Olympus, Daiichi Sankyo, MSD, and Terumo. Takao Tamura received research grants from Ono Pharmaceutical, Bristol Myers Squibb, MSD, Merck Serono, Daiichi Sankyo, Takeda Pharmaceutical, and Chugai Pharmaceutical and personal fees from Daiichi Sankyo and Takeda Pharmaceutical. Do-Youn Oh received research grants from Astra Zeneca. Yee Chao, Won Ki Kang, Sang Cheul Oh, Li-Yuan Bai, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Keiko Minashi, Jae Yong Cho, Keun-Wook Lee, and Masahiro Tsuda received research grants from Ono Pharmaceutical. Mitsunobu Tanimoto is an employee of Ono Pharmaceutical. Li-Tzong Chen received research grants from Ono Pharmaceutical, Bristol Myers Squibb, Ministry of Science and Technology, Taiwan, Ministry of Health and Welfare, Taiwan, Novartis, Pfizer, TTY Biopharm, OBI Pharma, Polaris Pharma, Syncore Biotechnology, and Celgene, personal fees from Ono Pharmaceutical, Bristol Myers Squibb, Novartis, Eli Lilly, TTY Biopharm, PharmaEngine, Shire, MSD, Five Prime Therapeutics, AstraZeneca, and Ipsen, and non-financial support from Novartis, TTY Biopharm, PharmaEngine, Syncore, and Celgene. Narikazu Boku received research grants from Ono Pharmaceutical and Taiho Pharmaceutical and personal fees from Ono Pharmaceutical, Chugai Pharmaceutical, Merck Serono, AstraZeneca, and Taiho Pharmaceutical.
: The present paper report results from post hoc analysis of ATTRACTION-2 (ClinicalTrials.gov ID: NCT02267343) trial. All procedures performed involving human participants in ATTRACTION-2 trial were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: The protocol of the ATTRACTION-2 trial was approved by the institutional review board or independent ethics committee for each study center. Written informed consent was obtained from all patients.